BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
PALO ALTO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will present at the Bank of America Merrill Lynch Global Healthcare Conference 2024 in Las Vegas, NV on Wednesday, May 15 at 3:00 pm PT.
加利福尼亚州帕洛阿尔托，2024年5月14日（GLOBE NEWSWIRE）——专注于遗传性疾病和癌症的商业阶段生物制药公司BridgeBio Pharma, Inc.（纳斯达克股票代码：BBIO）（“BridgeBio” 或 “公司”）今天宣布，其管理团队成员将于周三出席在内华达州拉斯维加斯举行的2024年美国银行美林证券全球医疗保健会议。太平洋时间 5 月 15 日下午 3:00
To access the live webcast of BridgeBio's presentation, please visit the "Events & Presentations" page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcast will be available on the BridgeBio website for 90 days following the event.
要观看BridgeBio演讲的网络直播，请访问BridgeBio网站投资者部分中的 “活动与演讲” 页面，网址为 http://investor.bridgebio.com。网络直播的重播将在活动结束后的90天内在BridgeBio网站上播出。
About BridgeBio Pharma, Inc.
关于 BridgeBio 制药公司
BridgeBio Pharma, Inc. (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio's pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers, and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn and Twitter.
BridgeBio Contact:
Vikram Bali
contact@bridgebio.com
(650)-789-8220
BridgeBio 联系
巴厘岛维克拉姆
contact@bridgebio.com(650) -789-8220